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Type 1 interferon (IFN) inhibits the release of
HIV-1 virus particles via poorly defined mecha-
nisms. Here, we show that IFNa induces
retention of viral particles on the surface of
fibroblasts, T cells, or primary lymphocytes
infected with HIV-1 lacking the Vpu protein. Re-
tained particles are tethered to cell surfaces,
can be endocytosed, appear fully assembled,
exhibit mature morphology, and can be de-
tached by protease. Strikingly, expression of
the HIV-1 Vpu protein attenuates the ability of
human cells to adhere to, and thereby retain,
nascent HIV-1 particles upon IFNa treatment.
Vpu also counteracts the IFNa-induced reten-
tion of virus-like particles assembled from the
Ebola virus matrix protein. Furthermore, levels
of IFNa that suppress replication of Vpu-defec-
tive HIV-1 have little effect on wild-type HIV-1.
Thus, we propose that HIV-1 expresses Vpu to
counteract an IFNa-induced, general host de-
fense that inhibits dissemination of enveloped
virions from the surface of infected cells.
INTRODUCTION
Type 1 interferons (IFNs) are a major component of the in-
nate immune response that limits systemic dissemination
of viral infections and drives adaptive responses required
for viral clearance and protection (Stetson andMedzhitov,
2006). The expression and release of IFNs from virus-in-
fected cells is triggered by recognition of extra- and intra-
cellular molecular patterns such as double-stranded RNA
and aberrant glycosylation resulting from viral replication.
The IFNa family (released mainly by lymphoid dendritic
cells) and IFNb (released from most somatic cells) bind
to IFNa/b receptors and induce the expression of IFN-
regulated genes via STAT-dependent signaling (van
Boxel-Dezaire et al., 2006). In addition to enhancing the
presentation and recognition of viral antigens (Stetson
andMedzhitov, 2006), some type 1 IFN-induced genes di-Cell Host & Mrectly inhibit viral replication (Samuel, 2001). For example,
the GTPases MxA and MxB block replication of several
negative-strand RNA viruses, possibly by effecting sub-
cellular trafficking of viral components (Haller and Kochs,
2002), while 2050oligoadenylate synthase and RNaseL tar-
get viral RNAs for destruction (Samuel, 2001). While the
mechanisms of action of many IFN-induced antiviral pro-
teins are unknown, the broad spectrum of some activities
should make them difficult for viruses to avoid via simple
sequence variation. This provides an evolutionary impetus
for viruses to acquire completely new functions that neu-
tralize IFN-induced cellular defenses.
Retrovirus restriction factors, such as APOBEC3G and
TRIM5a (Bieniasz, 2004; Goff, 2004), that target HIV-1
can be IFN-regulated genes (Asaoka et al., 2005; Peng
et al., 2006; Tanaka et al., 2006), suggesting that these
mediators of intrinsic immunity to retroviruses are special-
ized extensions of the wider innate antiviral defense.
Moreover, some clinical observations (Levy et al., 2003;
Siegal et al., 2001) suggest that IFNa may inhibit HIV-1
replication in vivo. While IFNa can suppress HIV-1 replica-
tion in cultured T cells andmacrophages (Poli et al., 1989),
the precise mechanism by which replication is inhibited is
not clear. Although some reports suggest IFNa-induced
blocks in HIV-1 reverse transcription and gene expression
(Shirazi and Pitha, 1992, 1993), the most commonly ob-
served effect of IFNa on HIV-1 replication is inhibition of
the release of progeny virions from infected cells (Gottlin-
ger et al., 1991; Kornbluth et al., 1989; Poli et al., 1989). g-
retrovirus and b-retrovirus release can also be inhibited by
IFNa (Bilello et al., 1982; Chatterjee and Hunter, 1987).
Microscopic studies of IFNa-treated infected T cells, mac-
rophages, and cell lines indicate that HIV-1 particles can
accumulate prominently at the plasma membrane and in
undefined intracellular vacuoles (Biswas et al., 1992;
Kornbluth et al., 1989; Smith et al., 1991).
Viral protein U (Vpu), a small integral membrane protein
encoded by HIV-1 and its closest relatives (Hout et al.,
2004), can facilitate HIV-1 particle release from some
cells, and its absence can result in HIV-1 particle accumu-
lation within and on infected cells (Gottlinger et al., 1993;
Klimkait et al., 1990). Importantly, Vpu appears to over-
come a host activity that blocks retrovirus particle release
in some restrictive human cell types (Varthakavi et al.,icrobe 2, 193–203, September 2007 ª2007 Elsevier Inc. 193
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ticles accumulated prominently within late endosomes of
restrictive cells and, particularly when their internalization
was prevented, on cell surfaces (Neil et al., 2006). Kinetic
and other analyses of HIV-1 Gag accumulation in nonper-
missive cells suggest that, in the absence of Vpu, HIV-1
Gag initially targets the plasma membrane, assembles,
and then is reinternalized as fully assembled virions (Harila
et al., 2006; Neil et al., 2006). Moreover, HIV-1 particles
Figure 1. IFNa Specifically Blocks the Release of Vpu-Defec-
tive HIV-1 Particles
(A) 293T or HeLa cells were infected with VSV-G-pseudotyped HIV-
1(WT) or HIV-1(del Vpu) at an moi of 0.2 and then treated with the
indicated dose of IFNa. Extracellular particles and cell lysates were
harvested and analyzed by western blotting using an anti-p24CA
monoclonal antibody.
(B) Same as (A) except that infectious virions in culture supernatants
were measured using HeLa-TZM indicator cells and a chemilumines-
cent assay and expressed in relative light units (RLU). Error bars indi-
cate the standard deviations of the mean.
(C) Jurkat T cells were infected as in (A) with VSV-G-pseudotyped, en-
velope-defective mutants of HIV-1(WT) or HIV-1(del Vpu) and were left
untreated () or were treated with 1000 U/ml IFNa (+).194 Cell Host & Microbe 2, 193–203, September 2007 ª2007 Elsthat accumulate on restrictive cell surfaces were fully ma-
ture and could be removed by protease treatment, sug-
gesting that a host protein tethers nascent HIV-1 virions
to the surface of restrictive cells.
Given the superficial morphological similarities associ-
ated with the blocks to HIV-1 particle release observed in
the absence of Vpu or upon treatment of infected cells
with IFNa, we exploredwhether these blocks were directly
related. Significantly, IFNa treatment of fibroblast and T
cell lines, inwhich Vpu is not ordinarily required for efficient
HIV-1 release, induced the retention of particles via a pro-
tease-sensitive tether, as well as their accumulation of in
late endosomes. Notably, these effects were much more
pronounced, and sometimes only evident, when Vpu was
absent. Furthermore, Vpu deletion caused HIV-1 replica-
tion in T cells to become more sensitive to inhibition by
IFNa. In addition, IFNa blocked the release of enveloped
particles assembled using an unrelated viral structural pro-
tein. Thus, these studies suggest that HIV-1 acquired the
Vpu protein at least in part to overcome an IFN-induced
host defensemechanism that tethers nascent virions to in-
fected cells and prevents their dissemination.
RESULTS
Type 1 IFN Induces a Block in Vpu-Defective HIV-1
Release
To test the notion that IFNa-induced and Vpumutation-in-
duced blocks in HIV-1 release were related, we compared
the properties of an HIV-1 strain, NL4-3 [HIV-1(WT)], with
a Vpu-deleted counterpart [HIV-1(del Vpu)]. 293T and
HeLa cells were infected with mixed vesicular stomatitis
virus glycoprotein (VSV-G) pseudotypes of each virus,
and, thereafter, HIV-1 protein expression and particle yield
were determined using western blot and infectivity assays
(Figure 1). Since neither cell type expresses CD4, this pro-
cedure resulted in a single cycle of HIV-1 replication. As
expected, and despite equivalent levels of Gag expres-
sion, the release of HIV-1(del Vpu) particles from HeLa
cells was severely reduced as compared to HIV-1(WT)
particles, and increased levels of processed p24 protein
remained associated with the cells (Figure 1A). In contrast,
approximately equivalent levels of HIV-1(WT) and HIV-1
(del Vpu) particles were released by infected 293T cells.
However, while the release of HIV-1(del Vpu) particles
from 293T cells was increasingly impaired upon treatment
with increasing doses of IFNa, the release of HIV-1(WT)
was only marginally affected by IFNa treatment. Indeed,
IFNa-treated 293T cells exhibited a phenotype that re-
sembled that of untreated HeLa cells, where HIV-1 release
was highly dependent on Vpu. Notably, inefficient HIV-1
(del Vpu) release from HeLa cells was not further inhibited
by IFNa. Measurements of infectious particle release by
293T and HeLa cells were largely concordant with these
results. Specifically, 10–1000 U/ml IFNa induced an 10-
fold reduction in the yield of infectious HIV-1(del Vpu)
particles, specifically from 293T cells, while infectious
HIV-1(WT) particle yield was unaffected at the same doses
of IFNa. At very high concentrations of IFNa (10,000 U/ml),evier Inc.
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lines, irrespective of Vpu expression (Figure 1B). To dem-
onstrate formally that Vpu was responsible for the IFNa
resistance of HIV-1(WT), 293T cells were transfected with
HIV-1(WT) and HIV-1(del Vpu) proviral plasmids, and a
plasmid that would express Vpu in trans. Again, the gener-
ation of infectious HIV-1(del Vpu) particles was impaired
by IFNa, with little effect on HIV-1(WT). However, expres-
sion of Vpu in trans caused HIV-1(del Vpu) to be resistant
to the inhibitory effect of IFNa (Figure S1 in the Supple-
mental Data available with this article online).
To determinewhether a similar effect could be observed
in cells that more closely resemble natural targets of HIV-1
infection, CD4+ Jurkat T cells were infected with VSV-G-
pseudotyped HIV-1(WT) and HIV-1(del Vpu). In this case,
envelope-defective HIV-1 constructswere used to prevent
multiple rounds of replication, or cell fusion. A marginal ef-
fect of Vpu on the release of HIV-1 particles fromuntreated
Jurkat cells was observed (Figure 1C). However, IFNa
treatment selectively decreased the release of HIV-1(del
Vpu) particles and also increased in the level of cell-asso-
ciated processed p24. Taken together, these results dem-
onstrate that the requirement for Vpu can be induced
by IFNa treatment of cells that normally do not restrict
Vpu-defective HIV-1 particle release, leading to a pheno-
type that resembles that observed in restrictive cells
(e.g., HeLa), where the requirement for Vpu is constitutive.
Figure 2. HIV-1 Vpu Antagonizes IFNa-Induced Inhibition of
HIV-1 Release in Human 293T Cells but Not in African Green
Monkey COS Cells
(A) 293T cells (left panels) or COS-7 cells (right panels) were infected
with VSV-G-pseudotyped HIV-1(WT) or HIV-1(del Vpu) at an moi of
0.2 and then treated with the indicated dose of IFNa. Extracellular par-
ticles and cell lysates were analyzed by western blotting using an anti-
p24CA monoclonal antibody.
(B) Same as (A), except that infectious virions in culture supernatants
were measured using HeLa-TZM indicator cells, as in Figure 1. Error
bars indicate the standard deviations of the mean.Cell Host & MVpu Suppression of the IFNa-Induced Block
in HIV-1 Release Is Cell Type Specific
Another cell line in which Vpu was shown previously not
to be required for efficient HIV-1 particle release is the
African green monkey (AGM) cell line COS-7. IFNa again
dramatically inhibited the release of HIV-1 particles from
COS-7 cells without affecting viral Gag protein expres-
sion, or processing (Figure 2A). However, in this case both
HIV-1(del Vpu) andHIV-1(WT) were similarly affected, indi-
cating that Vpu was unable to counteract the IFNa-in-
duced block in this cell type. Nonetheless, in the same
experiment, Vpu clearly reversed an IFN-induced block
to HIV-1 released in 293T cells (Figure 2A). Measurements
of infectious HIV-1(WT) and HIV-1(del Vpu) virion release
gave essentially the same result, in that infectious particle
production from COS-7 cells was inhibited up to 100-fold
by IFNa, irrespective of the presence or absence of Vpu, in
contrast to 293T cells (Figure 2B). Thus, the ability of Vpu
to counteract the IFNa-induced inhibition of HIV-1 release
was cell type specific, and Vpu failed to function in at least
one cell line from a nonhuman species.
IFNa Induces Accumulation of HIV-1 Particles
on Cell Surfaces and in Endosomes
Previously, we showed that HIV-1(del Vpu) particles accu-
mulate in HeLa cell endosomes, as a result of endocytosis
of fully assembled particles that were retained on the
plasma membrane. To determine whether IFNa treatment
of 293T cells induced a similar outcome, we infected 293T
cells (Figure 3A) andHeLa cells (Figure 3B)with fluorescent
derivatives of HIV-1(WT) and HIV-1(del Vpu) that carry a
fluorescent protein (YFP) inserted into the stalk region of
the matrix domain of Gag (MA-YFP) (Jouvenet et al.,
2006). Theproportion of cells inwhich visible internal accu-
mulations of MA-YFP could be seen (examples are shown
in Figures 3A and 3B) was then determined (Figure 3C). In
both 293T and HeLa cells, MA-YFPwas observed as a dif-
fuse cytoplasmic fluorescent signal, with accumulations of
greater fluorescent intensity at the plasmamembrane in all
infected cells. In addition, intense intracellular accumula-
tions ofMA-YFPwere observed, but this was a rare finding
in 293T cells and occurred in <10% of cells infected with
HIV-1/MA-YFP(WT) (Figures 3A and 3C). Notably, IFNa
did not change the distribution of the HIV-1/MA-YFP(WT)
signal. Moreover, 293T cells infected with HIV-1/MA-YFP
(del Vpu) exhibited a similar pattern of YFP fluorescence;
only a small minority (<10%) of cells exhibited intracellular
accumulations (Figures 3A and 3C). In marked contrast,
the number of HIV-1/MA-YFP(del Vpu) infected cells
that displayed intense intracellular accumulations was in-
creased by IFNa treatment, to 40% of all infected cells
(Figures 3A and 3C). As expected from our previous
studies (Neil et al., 2006), intracellular accumulations of
MA-YFP were observed in only a small fraction of HeLa
cells infected with HIV-1/MA-YFP(WT), while prominent
intracellular accumulations were observed in 60% of
HeLa cells infected with HIV-1/MA-YFP(del Vpu) (Figures
3Band3C). Notably, IFNahad noadditional effect on intra-
cellular MA-YFP accumulation in HeLa cells (Figure 3C).icrobe 2, 193–203, September 2007 ª2007 Elsevier Inc. 195
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Interferon-Induced Tethering of Nascent VirionsFigure 3. Nascent Vpu-Defective HIV-1 Particles Accumulate in Endosomes of IFNa-Treated 293T Cells
(A) 293T cells were infected with VSV-G-pseudotyped HIV-1/MA-YFP(WT) or HIV-1/MA-YFP(del Vpu) encoding a modified matrix protein with YFP
inserted into the stalk region. Cells were treated with 1000 U/ml IFNawhere indicated and examined by deconvolution microcopy. Two examples are
shown for each condition.
(B) A single representative example of HeLa cells infected with VSV-G-pseudotyped HIV-1/MA-YFP(WT) or HIV-1/MA-YFP(del Vpu), as indicated.
(C) The proportion of cells with intense MA-YFP accumulation at the plasma membrane (PM) only, or both at internal sites and plasma membrane
(Internal + PM), was quantified for 293T cells or HeLa cells, as indicated following infection with HIV-1/MA-YFP(WT) or HIV-1/MA-YFP(del Vpu). Cells
were otherwise untreated, or were treated with 1000 U/ml IFNa. For each data point, between 60 and 100 individual cells were evaluated.
(D and E) HIV-1/MA-YFP(del Vpu)-infected, IFNa-treated (1000 U/ml) 293T cells were immunostained using antibodies against human CD63 (D) or
EEA-1 (E). Arrows indicate occasional MA-YFP puncta apparently colocalizing with EEA-1+ early endosomes. Scale bars represent 10 mm, except
in the lower panels of (E), where they indicate 1 mm.To determine the nature of IFN-induced intracellular ac-
cumulations of MA-YFP, 293T cells infected with HIV-1/
MA-YFP(del Vpu) were stained with antibodies to the early
endosome marker EEA-1 or the late endosomal marker
CD63. As can be seen in Figures 3D and 3E, there was
prominent colocalization of MA-YFP with CD63+ late en-
dosomes and occasional colocalization of MA-YFP with
EEA1+ early endosomes in IFNa-treated 293T cells. This
IFNa-induced pattern of HIV-1 Gag localization is remark-
ably similar to that previously observed in HeLa cells,
where Vpu-defective HIV-1 particles are constitutively re-
tained on the cell surface and then endocytosed (Neil
et al., 2006). Thus, this finding suggested that the IFNa-196 Cell Host & Microbe 2, 193–203, September 2007 ª2007 Elinduced block results in particle retention, internalization,
and accumulation in endosomes.
Electron microscopic imaging was used to characterize
the nature of the IFNa-induced virus release defect in
greater detail. These analyses were performed using
COS-7 cells transfected with the HIV-1(WT) or HIV-1(del
Vpu) proviral constructs and then treated with IFNa (Fig-
ure 4) because the flat shapeand large cytoplasmic volume
of these cells was optimal for visualizing both internal and
cell surface-associated virions. As was the case with in-
fected COS-7 cells (Figure 2), both HIV-1(WT) and HIV-1
(del Vpu)were efficiently released by transfected but other-
wise untreated COS-7 cells. However, particle releasewassevier Inc.
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Interferon-Induced Tethering of Nascent VirionsFigure 4. Thin-Sectioned ElectronMicroscopic Images of Cells and Virions under ConditionsWhereReleaseWas Inhibited by IFNa
(A) Overview of a COS cell transfected with the HIV-1(del Vpu) proviral plasmid, but otherwise untreated. Arrows indicate examples of cell-associated
virions (expanded view is shown in inset).
(B) Accumulations of mature HIV-1(WT) virions apparently adhered to the surface of COS-7 cells upon treatment with 500 U/ml IFNa. Note that anal-
ogous clusters were not seen in the absence of IFNa treatment. Arrows indicate virions within the lumen of endosomal compartments.
(C) Expanded image of HIV-1(WT) particles within the endosomal compartments of an IFNa-treated cell. Individual mature viral particles are high-
lighted.
(D) Image showing surface accumulations of mature HIV-1(del Vpu) virions apparently adhered to the surface of COS-7 cells treated with 500 U/ml
IFNa.
(E) Image showing HIV-1(del Vpu) particles within the endosomal compartments of an IFNa-treated cell. Individual mature viral particles are high-
lighted with arrows.
(F) Surface accumulations of HIV-1(WT) mature virions adhered to the cell surface or to each other on an IFNa-treated cell. Note that the accumulation
of virus within endosomal compartments was not observed in cells expressing the endocytosis inhibitor Rab5a(S34N).
(G and H) Expanded images of surface-associated HIV-1(WT) virions (G) or HIV-1(del Vpu) virions (H) in cells treated with IFNa and expressing
Rab5a(S34N). Arrows highlight sites where virions appear to be adhered to the cell surface or to one another via external ‘‘tethers.’’ Scale bars in
all panels represent 100 nm.strongly inhibitedby IFNa treatment, asmeasured by either
western blot or infectivity assays (Figure S2).
Thin-section EM images of virus-producing, but other-
wise untreated, COS-7 cells revealed only rare examples
of cell-associated virions, whether or not Vpu was ex-
pressed (Figure 4A). In marked contrast, IFNa induced
the striking accumulation of large numbers of mature par-
ticles associated with the cell surface and intracellular
compartments (Figures 4B–4E). Although single particles
or small clusters of particles were occasionally observed
in association with the cell surface in the absence of IFNa
treatment, such large-scale surface clustering of virionsCell Host & Mwas never seen in untreated control cells (Figure 4A). In-
deed, we estimated that there was an approximately
100-fold greater density of mature particles on the surface
of IFNa-treated cells compared to control cells (Figures
4A, 4B, and 4D). We therefore conclude that HIV-1 virions
bud andmature normally in the presence of IFNa, but then
remain aberrantly tethered to the outer cell surface.
IFNa treatment also caused the prominent accumula-
tion of mature virions in internal cellular compartments
(Figures 4C and 4E), which are likely endosomes, based
upon the fluorescence colocalization experiments de-
scribed above. Consistent with this assignment, theicrobe 2, 193–203, September 2007 ª2007 Elsevier Inc. 197
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ways) contained small vesicles and other membranous
structures and therefore resembled late endosomal multi-
vesicular bodies (Figure 4E). Significantly, the accumula-
tion of virion-containing endosomes was dependent on
IFNa treatment, as intracellular virions were rarely ob-
served in control producer cells that were not IFNa treated
(Figure 4A). Presumably because COS-7 cells are not re-
sponsive to Vpu, these observations were essentially in-
distinguishable when HIV-1(WT) (Figures 4B and 4C) or
HIV-1(del Vpu) (Figures 4D and 4E) was used.
The accumulation of virion-containing endosomes re-
quired active endocytosis, because internal virions were
absent from IFNa-treated cells in which HIV-1 WT or
HIV-1(del Vpu) was coexpressed with Rab5a(S34N),
whose expression inhibits uptake of endocytic cargo
(Bucci et al., 1992; Li and Stahl, 1993; Stenmark et al.,
1994). Importantly, Rab5a expression in itself did not
affect virion release (Figure S2) or the appearance of
rare virions on cells that were not treated with IFNa (data
not shown). The phenotypic difference induced by Rab5a
(S34N) expression in IFNa-treated cells was highly signif-
icant, as virion-containing endosomes were observed in
most (>75%) of the IFNa-treated cells in which endocyto-
sis was not blocked and where internal endosomes/
vacuolar structures were visible. In contrast, endosomal
virions were never observed when endocytosis was
blocked by Rab5a(S34N) expression. Nonetheless, the
abundant appearance of mature virions clustered on the
surface of IFNa-treated cells was maintained whether or
not Rab5a(S34N) was coexpressed (Figures 4F–4H).
Expanded EM images revealed that cell-associated
virions remained closely juxtaposed to the cell surface
and to one another (Figures 4G and 4H). These ‘‘tethered’’
virions were fully mature and had complete, intact outer
membranes, implying that tethering interactions were me-
diated by molecules on the cell/virion exterior. Indeed,
such external linkages sometimes appeared visible in
the thin-sectioned EM images of tethered particles (Fig-
ures 4G and 4H, arrows). Thus, the block to virus release
observed upon IFNa treatment appears to be mediated
by a cell surface molecule(s) that causes mature HIV-1
virions to adhere to the cell surface and to one another.
IFNa Induces Protease-Sensitive Tethering
of Nascent HIV-1 Particles
In HeLa cells, where the requirement for Vpu in HIV-1
release is constitutive, Vpu-defective viruses remain
adhered to infected cell surfaces in a form that is morpho-
logically similar to that shown in Figure 4, where particle
release was inhibited by IFNa. Particles that are constitu-
tively retained by HeLa cells due to the absence of Vpu
can be liberated by the protease subtilisin, particularly
when their endocytosis is blocked (Neil et al., 2006). Pro-
tease-induced release of mature particles distinguished
Vpu-defective HIV-1 from late budding domain mutants
that remain cell associated, even upon protease treat-
ment, because in that case, the cell and virion membranes
are continuous (Neil et al., 2006). To determine whether198 Cell Host & Microbe 2, 193–203, September 2007 ª2007 EIFNa treatment led to protein-mediated tethering of ma-
ture particles to infected cells, 293T cells, Jurkat cells, or
primary peripheral blood mononuclear cells (PBMCs)
were infected with HIV-1(WT) or HIV-1(del Vpu) and cul-
tured with or without IFNa. Envelope-defective, VSV-G-
pseudotyped, viral constructs were used for these exper-
iments to remove any confounding effects of gp120:CD4
interactions that might be affected by Vpu, and to restrict
the assay to a single round of virus replication. Constitu-
tively released particles were harvested from the culture
supernatant, as were particles liberated from cells either
by buffer washing or by protease ‘‘stripping.’’ In 293T cells
infected with HIV-1(WT) (Figure 5A), most of the HIV-1 par-
ticles that could be recovered were constitutively re-
leased, and only a small proportion could be recovered
from cell surfaces by protease stripping. This was also
true when HIV-1(WT)-infected 293T cells were treated
with IFNa. When 293T cells were infected with HIV-1(del
Vpu), most particles were, again, constitutively released.
However, in contrast to HIV-1(WT), when HIV-1(del Vpu)-
infected 293T cells were treated with IFNa, a relatively mi-
nor fraction of particles were constitutively released, and
instead, most particles were recovered from cell surfaces
by protease stripping (Figure 5A).
Analogous experiments, done using Jurkat T cells and
PBMCs, yielded similar, but even more striking results
(Figures 5B and 5C). In Jurkat cells infected with HIV-1
(WT), a minor fraction of particles were retained on cell
surfaces in a form that could be liberated by protease
treatment, and this fraction was slightly increased by
IFNa treatment (Figure 5B). In HIV-1(del Vpu)-infected Ju-
rkat cells, the majority of particles were retained on cell
surfaces, but some particles were constitutively released.
Notably, HIV-1(del Vpu) particle release was dramatically
inhibited by IFNa. Indeed, almost no particles were re-
leased by IFNa-treated, HIV-1(del Vpu)-infected cells,
and instead virtually all of the extracellular particles that
could be recovered required protease stripping from the
cell surface (Figure 5B). In PBMCs, the effects of IFNa
and Vpu deletion were less dramatic than in Jurkat cells,
perhaps because PBMCs contain a mixture of cell types.
Nevertheless, IFNa had no detectable effect on HIV-
1(WT) particle release but clearly inhibited constitutive
HIV-1(del Vpu) release. Moreover, IFNa increased the pro-
portion ofHIV-1(del Vpu) particles thatwere recovered only
after protease stripping (Figure 5C). Notably, in both Jurkat
cells, and particularly PBMCs, protease stripping removed
most, andsometimesall, of thedetectablematurep24cap-
sid protein fromcells, while the level of cell-associatedGag
precursor was unaffected (Figures 5B and 5C). This sug-
gests that the majority of the cell-associated mature p24
protein was in the form of particles attached to the surface
by a protease-sensitive tether. Notably, both Vpu deletion
and IFNa treatment increased the amount of fully pro-
cessed p24, presumably representing mature virus, that
was retained by cells, and could therefore only be recov-
ered in particulate form from cells by protease stripping.
Overall, in cells that exhibit no constitutive requirement
(293T) or a partial requirement (Jurkat cells and PBMCs)lsevier Inc.
Cell Host & Microbe
Interferon-Induced Tethering of Nascent VirionsFigure 5. Protease-Sensitive Tethers Retain Nascent Parti-
cles on the Surfaces of IFNa-Treated Cells
293T cells (A), Jurkat cells (B), or primary PBMCs (C) were infected with
VSV-G-pseudotyped, envelope-defective HIV-1(WT) or HIV-1(del Vpu)
and cultured in the presence or absence of 1000 U/ml IFNa. Cell ly-
sates and extracellular particles that were either constitutively releasedCell Host & Mfor Vpu in particle release, IFNa treatment selectively in-
creased the retention of Vpu-defective, mature particles
linked to the cell by a protease-sensitive tether. While
the precise nature of the phenotype associated with
293T cells, Jurkat cells, and PBMCs varied slightly, in all
cases Vpu clearly antagonized the ability of cells to retain
particles in response to IFNa treatment.
HIV-1 Replication Is Hypersensitive to IFNa
in the Absence of Vpu
Since IFNa selectively inhibited HIV-1(del Vpu) particle re-
lease from fibroblast and lymphocyte cells, we asked
whether Vpu deletion sensitizes HIV-1 replication to inhibi-
tion by IFNa. In Jurkat T cells, treatment with 100 U/ml
IFNa had only a minor effect on HIV-1(WT) replication,
as assessed by accumulation of infectious virions in cul-
ture supernatants (Figure 6A). Moreover, HIV-1(del Vpu)
replicated only slightly less efficiently than HIV-1(WT),
peaking at about the same time after inoculation, but at
a level that was a few-fold reduced compared to HIV-
1(WT), in agreement with previous studies (Strebel et al.,
1988). Strikingly, addition of 100 U/ml IFNa to infected
Jurkat cells 1 day after inoculation severely inhibited sub-
sequent HIV-1(del Vpu) replication, causing a 50- to 100-
fold reduction in the level of HIV-1(del Vpu) accumulation
at 7–9 days after inoculationwhen virus replication peaked
in the untreated cultures (Figure 6A). Similar results were
obtained using primary PBMCs from two donors as tar-
gets (Figure 6B). In both cases IFNa delayed the replica-
tion of HIV-1(WT), although similar yields of infectious vi-
rions were eventually obtained approximately 4–6 days
later. HIV-1(del Vpu) replicated less efficiently than HIV-
1(WT) in PBMCs, but replication nevertheless remained
quite robust (Figure 6B). Importantly, however, addition
of 100 U/ml IFNa almost completely blocked replication
of HIV-1(del Vpu) in PBMCs from both donors.
Effect of IFNa and Vpu on the Release of
a Nonretroviral Enveloped Virus-like Particle
Vpu is able to stimulate the release of retroviral particles
that share minimal protein sequence homology (Gottlinger
et al., 1993). This raises the possibility that IFNa-mediated
tethering simply involves host molecule-mediated adhe-
sion of virion and host cell membrane bilayers to each
and does not require any retrovirus-specific molecules.
Therefore, we next determined whether the release of an
unrelated, nonretroviral virus-like particle could be in-
hibited by IFNa and stimulated by HIV-1 Vpu. We used
the Ebola virus VP40matrix protein because, like retroviral
Gag proteins, the expression of this protein alone can
generate extracellular particles that resemble authentic
virions. However, other than short sequence motifs that
are used to engage cellular machinery required for bud-
ding through the plasma membrane (Martin-Serrano
et al., 2001), retroviral Gag and filovirus matrix proteins
do not share any sequence or structural homology.
into the culture supernatant, or released following buffer or subtilisin
stripping, were pelleted and analyzed by western blotting.icrobe 2, 193–203, September 2007 ª2007 Elsevier Inc. 199
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was unaffected by the presence of coexpressed Vpu
(Figure 7A). In contrast, Ebola VP40 particle release from
HeLa cells was inefficient but was markedly enhanced
by coexpression of HIV-1 Vpu in trans. Additionally, treat-
ment of Ebola VP40-expressing 293T cells with IFNa
caused a dose-dependent decrease in virus-like particle
release without affecting VP40 expression (Figure 7B). No-
tably, the ability of IFNa to inhibit Ebola VP40 particle re-
lease was abolished when Vpu was expressed in trans.
Thus, the ability of IFNa to inhibit enveloped particle re-
lease extends beyond retroviruses, as does the ability of
Vpu to counteract IFNa-induced inhibition and stimulate
particle release.
DISCUSSION
While a large number of gene products, some of which are
presumed antiviral factors, are known to be upregulated
Figure 6. Replication of Vpu-Defective HIV-1 in Human CD4+
T Cells Is Hypersensitive to IFNa
CD4+ Jurkat T cells (A) or PBMCs from two donors (B) were infected
with HIV-1(WT) or HIV-1(del Vpu) and treated with 100 U/ml IFNa 24
hr after infection. Supernatant sampleswere harvested at the indicated
times thereafter, and infectious virus yield was measured using HeLa-
TZM cells and expressed in relative light units (RLU).200 Cell Host & Microbe 2, 193–203, September 2007 ª2007 Elas part of the innate immune response to viral infection, lit-
tle is known about how innate antiviral factors actually
work. The data presented herein strongly suggest that
a component of the type 1 interferon-induced response
causes tethering of nascent HIV-1 particles to the surface
of infected, virus-producing cells. In principle, this could
be a very effective way to attenuate a viral infection in vivo
and inhibit the dissemination of virus particles within a
host. Importantly, the ability of IFNa to inhibit particle re-
lease was observed at levels of interferon that are encoun-
tered systemically in HIV-1-infected individuals (Christeff
et al., 2002).
Previously, work on the HIV-1 Vpu protein has indicated
that cells can be categorized into two basic types, namely,
restrictive cells, such as HeLa, where Vpu is required for
efficient HIV-1 release, or permissive cells, such as COS,
HOS, or 293T, where HIV-1 release is not affected by
Vpu (Neil et al., 2006; Varthakavi et al., 2003). Hetero-
karyon experiments suggested that the difference be-
tween restrictive and nonrestrictive cells is the presence
or absence of a Vpu-targeted restriction factor (Varthakavi
et al., 2003). The results presented herein suggest that the
putative restriction factor(s) is a component of the type 1
interferon-induced innate immune response. Specifically,
IFNa treatment of several nonrestrictive or weakly restric-
tive human cell types, including natural HIV-1 target cells,
induced a particle retention phenotype that very closely
resembles that observed in restrictive cells, i.e., a block
to the production of new particles that could be overcome
by the Vpu protein. This block wasmanifested as an accu-
mulation of mature particles on cell surfaces, via a prote-
ase-sensitive tether, and in endosomes, presumably
Figure 7. Vpu-Stimulated Ebola Virus-like Particle Release
from HeLa Cells and IFNa-Treated 293T Cells
(A) 293T cells (left panels) and HeLa cells (right panels) were trans-
fected with a plasmid expressing HA-tagged Ebola virus VP40, and
HIV-1 Vpu as indicated. Cell and virus-like particle lysates were ana-
lyzed by western blotting.
(B) Same as (A) except that 293T cells were transfected with a plasmid
expressing HA-tagged Ebola virus VP40, in the presence or absence of
coexpressed HIV-1 Vpu and IFNa treatment, as indicated.sevier Inc.
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other virion-cell interactions that can occur during virion
production, i.e., those mediated by CD4 and gp120, can
also induce particle retention. However, in that case the
effect could be ameliorated by Nef- or Vpu-mediated
CD4 downregulation (Lama et al., 1999; Ross et al.,
1999). Importantly, the majority of experiments described
herein were done in cells that lack CD4, or with HIV-1
clones that lack an envelope gene, excluding gp120:CD4
interactions as mediators of this effect. While the identi-
ty(ies) of molecule(s) that are responsible for virion reten-
tion are unknown, IFNa appears to endow cells and/or
virions with an adhesive property that inhibits their disso-
ciation from one another. As such, IFN-induced cell adhe-
sion molecules, for example, would be reasonable candi-
dates for factors that induce virion retention. The finding
that virions, visualized by electron microscopy, appeared
to be tethered to each other as well as to cell surfaces,
also suggests that the molecule(s) involved in tethering
are incorporated into virions.
Vpucanenhance the releaseof diverse retroviruses from
restrictive cells (Gottlinger et al., 1993), implying that teth-
ering-based restriction acts on retroviruses in general, and
potentially, on other enveloped viruses that bud from the
plasma membrane. Moreover, in HIV-2 and some SIV iso-
lates that lack Vpu, an analogous function in virion release
maps to theenvelopegene (Abadaet al., 2005), suggesting
that antagonismofan IFN-inducedblock to virion release is
a conserved feature of primate lentiviruses. Additionally,
we found that Vpu can enhance the release of a very differ-
ent type of virus-like particle, generated by Ebola VP40.
This suggests that the tetheringmechanism isbroadly spe-
cific and perhaps is the result of promiscuous incorpora-
tion of adhesive molecules into the envelopes of virions
as they bud through the plasma membrane.
A conceptually related type of inhibition of enveloped
particle release occurs with influenza viruses, where cell
surface sialic acid can be bound by virion hemagglutinin
unless it is destroyed by the viral neuraminidase (Wagner
et al., 2002). However, in that case, sialic acid is constitu-
tively and universally expressed. Conversely, the apparent
inhibitor of HIV-1 and Ebola virus-like particle release is
IFNa induced in most cells. Moreover, the inhibitor(s)
may be variable in sensitivity to Vpu, because activity
could be counteracted by Vpu in several human cells,
while Vpuwas unable to counteract IFN-induced inhibition
of HIV-1 release in AGM COS cells. It is intriguing that
other antiretroviral molecules such as TRIM5a and APO-
BEC3G exhibit marked species-specific variation in se-
quence and properties as a result of apparently strong
positive selection during primate evolution. In the latter
case, the HIV-1 countermeasure (the Vif protein) is fully ca-
pable of counteracting the human variant of APOBEC3G
but is inactive against most nonhuman primate variants.
Our findings hint at the possibility that an analogous situ-
ation exists for Vpu and its target protein(s).
Some of the findings described herein differ, at least
superficially, from earlier studies in which a number of in-
vestigators have reported significant effects of IFNa on theCell Host &release and replication of what were presumed to be wild-
type HIV-1 strains. For example, several investigators
reported that IFNa inhibited the release of HIV-1 particles
into supernatants of infected cultures (Gottlinger et al.,
1991; Kornbluth et al., 1989; Poli et al., 1989) and induced
accumulation of HIV-1 particles on the surfaces (and
within) chronically infected T cells, macrophages, and
macrophage-like cells (Biswas et al., 1992; Kornbluth
et al., 1989; Smith et al., 1991). It is possible, however,
that at least some of these earlier studies employed
Vpu-defective viral strains, since several commonly used
laboratory-adapted HIV-1 strains, particularly clones de-
rived from the IIIB/LAV/Bru/Lai isolate used in several
studies (Biswas et al., 1992; Gottlinger et al., 1993; Poli
et al., 1989; Smith et al., 1991), harbor this lesion. Indeed,
Vpu mutations appear positively selected under culture
conditions that favor direct cell-to-cell transmission (Gum-
muluru et al., 2000), a finding that is entirely consistent
with the notion that the absence of Vpu favors retention
of completely formed, infectious virions on cell surfaces.
It is also possible that high levels of IFNa may inhibit
release, even in the presence of Vpu, perhaps by over-
whelming the capacity of Vpu to counteract inhibitors.
However, under normal conditions, efficient, Vpu-stimu-
lated virion release is likely to be important for an effective
spreading infection. The replication of an HIV-1 mutant
lacking a functional Vpu genewas hypersensitive to inhibi-
tion by IFNa, suggesting that the phenomenon of IFNa-in-
duced tethering is biologically relevant, and that at least
one role of the HIV-1 Vpu protein is to mitigate the antiviral
effects of type 1 IFN.
One recent report suggested a different mechanism for
IFNa-induced inhibition of HIV-1 release, namely that the
IFN-induced ubiquitin homolog ISG-15 blocks HIV-1 as-
sembly by disrupting the interactions between Gag and
Tsg101 (Okumura et al., 2006). Those results are difficult
to reconcile with the IFN-induced, mature virion retention
phenotype described herein. Specifically, disruption of
Gag:Tsg101 interactions causes a phenotype in which im-
mature virions containing partially processed Gag mole-
cules remain tethered to the cell due to a failure of cellular
and viral membrane scission (Demirov et al., 2002; Garrus
et al., 2001; Gottlinger et al., 1991; Martin-Serrano et al.,
2001). This ‘‘late budding’’ phenotype is very different
from the IFNa block described here, where the viral and
host cell membranes are discontinuous and the virions are
mature.Moreover, particlesarrestedata latebuddingstage
cannot be releasedbyprotease treatment (Neil et al., 2006),
while virions whose retention is induced by IFNa treatment
can be liberated by protease. Finally, we found that IFNa
morepotentlyaffectedHIV-1(delVpu) thanHIV(WT) release,
even thoughboth viruses should be equally sensitive to dis-
ruption of the Tsg101:Gag interaction.
Cells employ a variety of IFN-induced gene products to
retard replication of many viruses, but the mechanisms by
whichmany of these factors exert their effects is unknown.
Retention of nascent enveloped virions by adherence to
the surface of cells via an active, IFN-induced, tethering
mechanism that does not appear to require a specificMicrobe 2, 193–203, September 2007 ª2007 Elsevier Inc. 201
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general way for the innate immune response to inhibit
dissemination of a wide range of enveloped viruses.
EXPERIMENTAL PROCEDURES
Cells and Viruses
293T, HeLa, COS-7, HeLa-TZM, and Jurkat T cells were maintained
using standard procedures. Human PBMCs were isolated from blood
using Ficoll-paque gradient centrifugation, stimulated with phytohe-
magglutinin for 2 days, and then grown in the presence of IL-2
(20 U/ml, Roche) for a further 3 days before use.
HIV-1(WT) and HIV-1(del Vpu) versions of the HIV-1 molecular clone
NL4-3 have been previously described (Neil et al., 2006). Envelope-
defective derivatives, as well as derivatives carrying YFP in the stalk
region of matrix (HIV-1/MA-YFP), were constructed using standard
molecular biology techniques or have been described previously (Jou-
venet et al., 2006). Virus stocks were generated by transient transfec-
tion of semiconfluent 10 cm plates of 293T cells with 8 mg of plasmid
complexed with polyethylenimine. To generate VSV-G-pseudotyped
or mixed-pseudotyped virus stocks, 1 mg of pCMV-VSV-G was in-
cluded in the transfection. Virus-containing supernatants were har-
vested 48 hr posttransfection and filtered, and infectious titers were
determined as b-galactosidase+ colony-forming units using HeLa-
TZM indicator cells.
Virus Release Assays
For virus release assays involving adherent or suspension cells, 1 3
105 cells were plated per well of a 12-well plate. The next day the cells
were infected with VSV-G-pseudotyped virus stocks at an moi of 0.2,
and the inoculum was removed 6 hr later. Eighteen hours later, cells
were treated with or without recombinant human IFNa (Sigma), and
the cells were cultured for a further 24 hr. Supernatants were then har-
vested and filtered, and particles were pelleted through a 20% sucrose
layer at 30,000 g. Particle pellets and cell lysates were analyzed by
SDS-PAGE and western blot assays using a-p24 and a-mouse-perox-
idase antibodies, as previously described. To measure infectious virus
release from human cells, virus containing supernatants were serially
diluted and used to inoculate HeLa-TZM indicator cells. After 48 hr,
the HeLa-TZM cells were lysed, and b-galactosidase activity was de-
termined using a chemiluminescent assay.
Alternatively, 293T or HeLa cells were transfected with HIV-1 provi-
ral, Ebola VP40 (Martin-Serrano et al., 2004), and/or HIV-1 Vpu expres-
sion plasmids. IFNawas added to transfected cells at 24 hr after trans-
fection. Cells and extracellular particles were harvested 24 hr after
IFNa addition and analyzed as described above.
Virus Replication Assays
Jurkat cells or PBMCs (1 3 105) in 1 ml of medium were infected with
HIV-1(WT) or HIV-1(del Vpu) at an moi of 0.005. At 24 hr postinfection,
recombinant human IFNa (100 U/ml) was added to the cultures. Sam-
ples of supernatants were harvested at 48 hr intervals thereafter for the
ensuing 13–15 days and stored at 80C. Infectious virus titers in the
collected supernatant samples were determined using HeLa-TZM
indicator cells, as described above.
Fluorescent Microscopy
Cells were infected, as described above, with VSV-G-pseudotyped
HIV-1/MA-YFP derivatives at an moi of 0.2 and either were left un-
treated or were treated with 1000 U/ml IFNa. Microscopy was done
as described previously (Jouvenet et al., 2006; Neil et al., 2006). Mouse
monoclonal EEA1 (BD Biosciences) and CD63 (Chemicon) were used
to stain early and late endosomal compartments, respectively,
followed by an a-mouse Alexa Fluor 595 conjugate (Invitrogen).202 Cell Host & Microbe 2, 193–203, September 2007 ª2007 ElElectron Microscopy
COS-7 cells were transfected with HIV-1 plasmids (1.2 mg/well of
a 6-well plate) and, in some cases, cotransfected with the expression
construct for Rab5a(S34N) (0.3 mg/well) using FuGENE6 (Roche), ac-
cording to the manufacturer’s instructions. Control experiments con-
firmed the efficacy of the Rab5a(S34N) in inhibiting endocytosis of
the EGF receptor (data not shown) Fifteen hours posttransfection,
the media were changed and supplemented with 500 or 2500 U/ml
IFNa. Thirty-two hours later, the cell supernatants and cells were har-
vested for electron microscopy, western blot, and infectivity analyses,
as described previously (von Schwedler et al., 2003). Cells were fixed
with 2.5% glutaraldehyde/1% paraformaldehyde in cacodylate buffer
(0.1 M sodium cacodylate [pH 7.4], 35mM sucrose, 4 mMCaCl2). After
staining in 2% OsO4 and in 4% uranyl acetate, the cells were dehy-
drated in a graded ethanol series (50%–100%) and embedded in ep-
oxy resin Embed-812 (Electron Microscopy Sciences). Thin sections
(60–90 nm) were stained with saturated uranyl acetate, rinsed with
water, and then stained with Reynolds’ lead citrate. Electron micro-
graphs were taken on a Hitachi H-7100 transmission electron micro-
scope at an accelerating voltage of 75 kV. Note that only data from
the 500 U/ml treatments are shown in Figure 4, but very similar pheno-
types were observed upon treatment with 2500 U/ml.
Protease Stripping Experiments
Cells were infected with VSV-G-pseudotyped HIV-1(WT) or HIV-1(del
Vpu) and treated with IFNa as described above. Constitutively re-
leased particles were harvested from culture supernatants, and cells
in parallel wells were then either directly harvested or, alternatively, in-
cubated for 15min at 37C in 100 ml of Tris/HCl (pH 8.0), 150mMNaCl,
and 5mMCaCl2 with or without the addition of subtilisin (1 mg/ml). The
reaction was then stopped with 0.5 ml DMEM/FCS containing 5 mM
PMSF. Cells were pelleted and the supernatants were filtered (0.2 mm)
prior to harvesting released particles, by pelleting through sucrose, as
described above.
Supplemental Data
The Supplemental Data include two supplemental figures and can be
found with this article online at http://www.cellhostandmicrobe.com/
cgi/content/full/2/3/193/DC1/.
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